Swiss health care company Roche has launched the new global cancer immunotherapy Centers of Research Excellence (imCORE) Network and plans to invest up to CHF100m ($100m) in the project.
The network brings together global scientific and clinical experts in cancer immunotherapy to collaborate in investigating new treatment approaches.
The launch of imCORE is aimed at initiating pre-clinical and clinical research based on the latest scientific discoveries in addition to sharing data to accelerate the search for cancer cure.
As part of the project, new approaches would be identified to expand the number of people who benefit from cancer immunotherapy.
Roche global product development chief medical officer and head Sandra Horning said: “We believe the fastest way to advance progress against cancer is through collaboration, and consistent with our values, the goal of imCORE is to facilitate access to new technologies and emerging data among the top researchers around the world.
“imCORE represents our most recent commitment to collaborate with the global cancer community to further understand the biology and immunology of cancer, and to develop new treatments that may one day offer a cure for people with cancer.’’
The research network comprises 21 academic centres across the globe and is intended to support basic and clinical research collaboration to advance the science of cancer immunotherapy.
Scientists from these centres will work with scientists from Roche and Genentech, a member of the Roche group in the US to develop potential cures for people with cancer.
Roche is also collaborating with the network on existing and new investigational medicines, diagnostic technologies and emerging data.